- Improving human resources for health while scaling up ARV access in Ethiopia and Malawi
- Disruption to sending of HATIP edition 116
feedback
Give us your views on our work
Disruption to sending of HATIP edition 116
Due to a problem with the server that mails HATIP to subscribers, there were a number of disruptions to the mailing that took place on Friday September 5th. Some subscribers did not receive the correctly numbered edition, or received multiple copies of the test version, incorrectly numbered.
- If you received a HATIP edition numbered 115 on September 5th, this was a test edition that should only have gone to the editor.
- You should have received edition 116, Task shifting.
- If you did not receive edition 116 on task shifting, you can view the two articles in that edition at http://www.aidsmap.com/cms1277961.asp
We apologise for this disruption. Hopefully the mailing of this edition and future editions will proceed without technical hitches.
About HATIP
A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.
Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.
Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.
latest aidsmap news
- Multiple treatment failures occur less frequently but remain associated with high mortality rates in North American cohort
- People with HIV providing high quality treatment support in community
- International donors must not retreat from commitment to HIV treatment scale-up, MSF warns
- Reassurance for HIV-positive women about short-term risk of bone loss
- Circumcision protects gay men who have a 'preference' for insertive sex from HIV
- Certain manifestations of stigma especially hurtful for people with HIV
- GSK and Pfizer launch joint HIV venture, ViiV Healthcare
- New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
- President Obama announces US HIV travel ban will end in January 2010
- Darunavir/ritonavir, etravirine and raltegravir combination has 'remarkable' success in children with resistant virus